Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...
High Investment and Government Initiatives to Boost Rare Diseases Treatment ModalitiesRockville, MD, Nov. 13, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive ...